(Q36381000)

13 August 2017

1 reference

title

Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials (English)

1 reference

13 August 2017

main subject

cardiovascular disease

1 reference

Rainer H Böger

1

1 reference

13 August 2017

publication date

1 July 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

10 Suppl 1

1 reference

13 August 2017

page(s)

S19-25

1 reference

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Acute systemic inflammation impairs endothelium-dependent dilatation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Asymmetrical dimethylarginine: the Uber marker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L‐arginine in regenerated endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

Asymmetric dimethylarginine (ADMA) modulates endothelial function--therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1358863X05VM602OA

10.1191/1358863X05VM602OA

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference